Zealand Pharma major shareholder announcement: The Capital Group Companies, Inc.
December 25 2024 - 10:30AM
UK Regulatory
Zealand Pharma major shareholder announcement: The Capital Group
Companies, Inc.
Company announcement – No. 52 / 2024
Zealand Pharma major shareholder announcement: The Capital
Group Companies, Inc.
Copenhagen, Denmark, 25 December
2024 – Zealand Pharma A/S (“Zealand”)
(Nasdaq: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based
biotechnology company focused on the discovery and development of
innovative peptide-based medicines, today reports receipt on 23
December 2024 of notification pursuant to Section 38 of the Danish
Capital Markets Act from the following major shareholder:
As of 20 December 2024, The Capital Group Companies, Inc. held
voting rights corresponding to 6.20% of the total voting rights in
Zealand Pharma A/S. The Capital Group Companies notes that neither
The Capital Group Companies nor any of its affiliates own shares of
Zealand Pharma A/S for its own account. Rather, the shares reported
in this major shareholder notification are owned by accounts under
the discretionary investment management of one or more of the
investment management companies described in the notification form
attached.
Please see further details in the attached notification
form.
About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology
company focused on the discovery and development of peptide-based
medicines. More than 10 drug candidates invented by Zealand have
advanced into clinical development, of which two have reached the
market and three candidates are in late-stage development. The
company has development partnerships with a number of pharma
companies as well as commercial partnerships for its marketed
products.
Zealand was founded in 1998 and is headquartered in Copenhagen,
Denmark, with a presence in the U.S. For more information about
Zealand, please visit http://www.zealandpharma.com.
Contact:
Neshat Ahmadi (Investors)
Investor Relations Manager
Email: neahmadi@zealandpharma.com
Adam Lange (Investors)
Investor Relations Officer
Email: alange@zealandpharma.com
Anna Krassowska, PhD (Media and Investors)
Vice President, Investor Relations & Corporate
Communications
Email: akrassowska@zealandpharma.com
- Standard Form_Zealand_Pharma_AS_2024.12.20
Zealand Pharma AS (TG:22Z)
Historical Stock Chart
From Dec 2024 to Jan 2025
Zealand Pharma AS (TG:22Z)
Historical Stock Chart
From Jan 2024 to Jan 2025